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Abstract
Whether bevacizumab represents a feasible option for the ﬁrst-line treatment of unﬁt and elderly patients with
metastatic colorectal cancer remains controversial. The present meta-analysis included data from 782 patients
and provides evidence for the clinical beneﬁt yielded in terms of progression-free survival and overall survival
by the addition of bevacizumab to ﬁrst-line ﬂuoropyrimidine-based chemotherapy for these complex patients.
Background: Whether bevacizumab represents a feasible option for the ﬁrst-line treatment of unﬁt and elderly
patients with metastatic colorectal cancer (mCRC) remains controversial. The present systematic review and meta-
analysis evaluated the efﬁcacy and safety data of bevacizumab combined with ﬁrst-line ﬂuoropyrimidine mono-
chemotherapy for these complex patients. Patients and Methods: A systematic search of the published data was
conducted through May 31, 2016. The random-effects model was used to combine the effect estimates and the I2
index to quantify the between-study heterogeneity unexplained by sampling error. Results:We included 3 randomized
controlled trials, 4 single-arm phase II trials, and 1 prospective cohort study in the present meta-analysis (n¼ 782). The
monochemotherapy administered was capecitabine in 531 patients (67.9%) and 5-ﬂuorouracil in 251 (32.1%); 500
(63.9%) also received bevacizumab. The median age was 75 years, 441 patients (56.4%) were men, and the Eastern
Cooperative Oncology Group performance status was 0 to 1 in 684 patients (87.7%). The combination with bev-
acizumab produced advantages in terms of both progression-free survival (hazard ratio, 0.52; 95% conﬁdence in-
terval, 0.43-0.64; P < .00001; I2 ¼ 0%) and overall survival (HR, 0.79; 95% CI, 0.64-0.98; P ¼ .03; I2 ¼ 0%). The pooled
effect estimates of the randomized controlled trials have been previously reported. As expected, all-grade hyper-
tension (27% vs. 4.9%), bleeding (24% vs. 6.4%), thromboembolic events (10% vs. 5%), and proteinuria (25.6% vs.
8.2%) were more frequent in the bevacizumab combination group. Conclusion: Adding bevacizumab to ﬁrst-line
ﬂuoropyrimidine monochemotherapy signiﬁcantly improved progression-free and overall survival in unﬁt and elderly
patients with mCRC, with a manageable safety proﬁle and no unexpected toxicities.
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Bevacizumab Plus Fluoropyrimidines for Unﬁt or Older mCRC PatientsIntroduction
With a median age of diagnosis of > 70 years and more than one
third of all deaths occurring in patients aged > 80 years, colorectal
cancer (CRC) is predominantly a disease of the elderly.1 Although
systemic treatment has markedly evolved in recent years, how to best
approach geriatric or unﬁt populations remains a matter of debate,
with speciﬁc guidelines lacking. A widespread use of the geriatric
assessment has been advocated to improve patient selection; however,
evidence of its value in the decision-making process is limited.2 The
results from 4 randomized trials (ie, Medical Research Council
Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing [MRC
FOCUS], CApecitabine, IRinotecan, Oxaliplatin [CAIRO], Fe
́
dér-
ation Francophone de Cancérologie Digestive 2000-05 [FFCD
2000-05], and Australasian Gastro-Intestinal Trials Group Mito-
mycin, Avastin, Xeloda [AGITGMAX]) have shown that in patients
with advanced or metastatic CRC (mCRC), upfront combination
chemotherapy (doublet) was not superior to sequential treatment
beginning with 5-ﬂuorouracil (5-FU) alone in terms of survival.3-6
Hence, the upfront use of single-agent ﬂuoropyrimidine, given
either intravenously or orally,7 can still be considered a valid option
for frail, highly comorbid, or very old patients. Nevertheless, the
upfront use of doublet chemotherapy with 5-FU coupled with iri-
notecan or oxaliplatin has been shown to be as effective for older
patients as for younger subjects.8,9 However, the prescription of a
combination in clinical practice has been often restrained owing to
the potential for an increased risk of toxicity.10,11
Bevacizumab, the ﬁrst recombinant humanized monoclonal
antibody to vascular endothelial growth factor, is commonly used in
CRC in ﬁrst- and second-line therapy and between treatment lines.
A more rational use of the antiangiogenic strategy in the older or
unﬁt population has also been proposed12 based on results of
community-based registries, phase II studies, and a large, random-
ized phase III trial.13 Accordingly, subgroup analyses from ran-
domized trials have suggested a similar beneﬁt when adding
bevacizumab to chemotherapy for older or younger patients and
have not recommended using age alone as a speciﬁc criterion to
exclude patients from antiangiogenic treatment. Similarly, frail or
unﬁt patients with mCRC might still beneﬁt from doublet
chemotherapy regimens.14 Notwithstanding this large body of evi-
dence, both chemotherapy usage and biologic prescriptions decrease
for patients of advanced age.15,16
The aim of the present trial-level meta-analysis was to evaluate
the effect of adding bevacizumab to the most frequently used
cytotoxic regimens for mCRC patients who had been judged unﬁt
to receive an intense upfront treatment (because of age or frailty)
and to estimate the magnitude of this effect.
Patients and Methods
Types of Studies, Participants, Interventions, and
Outcomes
We included randomized controlled trials (RCTs) or prospective
cohort studies of patients with advanced or metastatic CRC. We
restricted the data to patients receiving monochemotherapy plus
bevacizumab because of advanced age or comorbidity. Data on the
following outcome measures were studied: objective response rate
(ORR), progression-free survival (PFS), and overall survival (OS).nical Colorectal Cancer Month 2016Search Strategy and Selection Criteria
The PubMed and EMBASE databases were searched for RCTs
and prospective cohort studies in May 31, 2016 with no language or
publication status restrictions. The search query for PubMed was as
follows: (“bevacizumab” [supplementary concept] OR “bev-
acizumab” [all ﬁelds]) AND (“colorectal neoplasms” [MeSH terms]
OR (“colorectal” [all ﬁelds] AND “neoplasms” [all ﬁelds]) OR
“colorectal neoplasms” [all ﬁelds] OR (“colorectal” [all ﬁelds] AND
“cancer” [all ﬁelds]) OR “colorectal cancer” [all ﬁelds]) AND
(“aged” [MeSH terms] OR “aged” [all ﬁelds] OR “elderly” [all
ﬁelds] OR unﬁt [all ﬁelds]). For EMBASE, the query was “bev-
acizumab”/exp OR “bevacizumab” AND (“aged”/exp OR “aged”
OR “elderly”/exp OR “elderly” OR “unﬁt”) AND (“colorectal tu-
mor”/exp OR “colorectal tumor” OR “colorectal carcinoma”/exp
OR “colorectal carcinoma” OR “colorectal neoplasm”/exp OR
“colorectal neoplasm” OR “colorectal cancer”/exp OR “colorectal
cancer”) AND [embase]/lim NOT [medline]/lim.
Ongoing studies and studies with < 10 patients per arm were
excluded.
Data Extraction
Two investigators (V.T., L.P.) independently screened the titles
and abstracts for inclusion. Full reports were retrieved for further
assessment if the information in the abstract suggested that the
study met all the prespeciﬁed criteria.
Two investigators (V.T., L.P.) were responsible for data assess-
ment and extraction. Details on the study design, participants,
setting, interventions, quality components, and efﬁcacy and safety
outcomes were recorded. Any inconsistency was resolved by dis-
cussion (F.P., G.M.).
For studies included in > 1 publication, the data were extracted
from all the publications. However, we considered the ﬁnal or
updated version of each trial as the primary reference. We included
trials in which patients crossed-over to the other treatment arm at
progression or received other treatment off-study and were analyzed
according to the arm to which they had been originally randomized.
We also extracted data from patient subgroups if these answered our
original question.
Statistical Analysis
The measure of association for PFS and OS was expressed as the
hazard ratio (HR). The measure of association for the ORR was the
odds ratio (OR). The estimation of the median time to PFS and OS
was calculated using the weighted average of the hazard rate with the
weights calculated by the inverse variance approach. The hazard rate
and its standard error were estimated using the median time as the
denominator under the assumption of exponential distribution. The
I2 index was calculated to estimate the heterogeneity among trials.
The random effects model was used for estimating and testing re-
sults in all analyses.
Although the efﬁcacy analyses included data from RCTs, the
safety analysis also incorporated data from cohort studies. The
determination of toxicity (all National Cancer Institute Common
Terminology Criteria for Adverse Events grades and grade 3-4)
focused on the main class of toxicities involving chemotherapy and
bevacizumab: hematologic, cardiovascular, and renal toxicity and
Carmine Pinto et alhypertension and bleeding. The quality of the RCTs was inde-
pendently evaluated by 2 of us (V.T., L.P.) using the approach
proposed by the Cochrane Collaboration for experimental studies;
the most conservative rate was considered for each item. The meta-
analysis was performed using Revman, version 5.2. The present
work was conducted and reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses guide-
lines for the reporting of systematic reviews and meta-analyses.17
Results
Published Data Search Results and Study Population
The PubMed and EMBASE database search produced 1714
studies published until May 31, 2016. After exclusion of duplicates
and irrelevant studies, 8 reports were deemed to be eligible for the
meta-analysis (Figure 1).13,18-24 Of the 8 studies, 3 were multicenter
RCTs (n ¼ 558)13,18,19 and 5 were phase II or prospective series
(n ¼ 224).20-24 The characteristics of the studies included are re-
ported in Supplemental Table 1 (available in the online version).
Patient age for inclusion was 70 or 75 years in 5 studies13,20-23
and 2 studies,18,24 respectively, and 65 years in 1 trial.19 The ma-
jor eligibility criteria are reported in Supplemental Table 2 (available
in the online version). The baseline characteristics of all patients
included in the analysis (n¼ 782) are listed in Table 1. Overall, 500
patients received capecitabine or 5-FU plus bevacizumab doublet
therapy and 282 received monochemotherapy alone. 5-FU-based
chemotherapy was the agent of choice for 251 patients, and all other
subjects (n ¼ 531) received capecitabine-based therapy. Almost allFigure 1 Flow Diagram of Systematic Published Data Searchpatients (87.7%) had an Eastern Cooperative Oncology Group
performance status of 0 to 1 and primary colon and/or rectal cancer
(primary site information was missing for only 18.3% of cases). The
study population was not pretreated for metastatic disease, with
approximately 77% of subjects not having received adjuvant ther-
apy. Among all patients, 70.9% and 41.4% had liver and lung
metastases, respectively, with 72.6% having already undergone
primary tumor resection. The main comorbidities were hyperten-
sion (53.9%), diabetes (20%), hypercholesterolemia (18.8%), and
atrial ﬁbrillation (14.6%).
ORR, PFS, and OS
Overall, 6 trials provided data for the ORR.13,19-23 The weighted
pooled ORRs were 33.3% (95% conﬁdence interval [CI], 21.7%-
44.9%) for the bevacizumab arms (P for heterogeneity < .001; I2 ¼
84%) and 12.1% (95% CI, 7%-17.1%) for the control arms (P for
heterogeneity ¼ .23; I2 ¼ 32%). In direct comparisons (2
RCTs),13,19 bevacizumab added to chemotherapy (5-FU or cape-
citabine) doubled the ORR compared with monochemotherapy
alone (OR, 2.05; 95% CI, 1.26-3.34; P ¼ .004; P for
heterogeneity ¼ .84; I2 ¼ 0%; Figure 2A).
All trials provided data for PFS and OS.13,18-24 The weighted
pooled median PFS was 9.4 months (95% CI, 8.2-11.2 months)
with the bevacizumab combinations (P for heterogeneity ¼ .55;
I2 ¼ 0%) and ranged from 5.1 to 5.5 months in the 2 control arms
with data available.13,19 Bevacizumab-based doublets reduced the
risk of progression by approximately 50% compared withClinical Colorectal Cancer Month 2016 - 3
Table 1 Baseline Patient Characteristics of Overall Population and Stratiﬁed by Study Design
Characteristic RCTs (n [ 558) Not Controlled (n [ 224) All Patients (n [ 782)
Age (years) (assumption of normality) 75 77 75
Male gender 325 (58.2) 116 (50.8) 441 (56.4)
ECOG PS
0-1 505 (90.8) 179 (79.9) 684 (87.7)
>1 51 (9.2) 45 (20.1) 96 (12.3)
Missing data 2 (0.4) 0 (0) 2 (0.3)
Primary site
Rectum 117 (24.5) 31 (19.3) 148 (23.2)
Colon 319 (66.7) 119 (73.9) 438 (68.5)
Rectum and colon 42 (8.9) 11 (6.8) 53 (8.3)
Missing data 80 (14.3) 63 (28.1) 143 (18.3)
Metastatic site number
1 70 (34.7) 102 (63) 172 (47.3)
>1 132 (65.3) 60 (37) 192 (52.7)
Missing data 356 (63.8) 62 (27.7) 418 (53.5)
Metastatic site
Liver 236/349 (67.6) 159/208 (76.4) 395/557 (70.9)
Lung 149/349 (42.7) 80/208 (38.5) 229/557 (41.4)
Previous treatment
Adjuvant CT
Yes 111 (22.7) 48 (21.4) 159 (22.3)
No 378 (77.3) 176 (78.6) 554 (77.7)
Missing data 69 (12.4) 0 (0) 69 (8.8)
RT
Yes 55 (11.2) 11 (7.6) 66 (10.4)
No 434 (88.8) 134 (92.4) 568 (89.6)
Missing data 69 (12.4) 79 (35.3) 148 (18.9)
Primary tumor resection
Yes 249 (71.3) 34 (82.9) 283 (72.6)
No 100 (28.7) 7 (17.1) 107 (27.4)
Missing data 209 (37.5) 183 (81.7) 392 (50.1)
Comorbidities
Hypertension 186/349 (53.3) 56/100 (56) 242/449 (53.9)
Myocardial infarction 24/349 (6.9) NR 24/349 (6.9)
Thromboembolic events 12/280 (4.3) NR 12/280 (4.3)
Diabetes 13/69 (18.8) 9/41 (22) 22/110 (20)
Angina pectoris 6/69 (8.7) NR 6/69 (8.7)
Hypercholesterolemia 13/69 (18.8) NR 13/69 (18.8)
Atrial ﬁbrillation NR 6/41 (14.6) 6/41 (14.6)
CVI or stroke 11/349 (3.2) NR 11/349 (3.2)
Transient ischemic attack 3/69 (4.3) NR 3/69 (4.3)
Neurologic disorders 16/280 (5.7) NR 16/280 (5.7)
Administered CT
Capecitabine 349 (62.5) 182 (81.2) 531 (67.9)
5-FU/LV 209a (37.5) 42b (18.8) 251 (32.1)
Data presented as median or frequency (n or n/total number of patients evaluated [%]).
Abbreviations: 5-FU ¼ 5-ﬂuorouracil; CT ¼ chemotherapy; CVI ¼ cerebrovascular infarction; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; LV ¼ leucovorin; NR ¼ not
reported; RCTs ¼ randomized controlled trials; RT ¼ radiotherapy.
aData from Tebbutt et al.5
bData from Kim10 (assuming a 2:1 ratio of 5-FU to capecitabine).
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Figure 2 Meta-Analysis Results for (A) Objective Response Rate, (B) Progression-Free Survival and (C) Overall Survival for Unﬁt or
Elderly Patients With Metastatic Colorectal Cancer Treated With Bevacizumab Plus Fluoropyrimidine-Based
Monochemotherapy (Experimental Arm) or Monochemotherapy Alone (Control Arm). Data Presented as Forest Plot Showing
Odds Ratios and 95% Conﬁdence Intervals (CI)
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Carmine Pinto et alchemotherapy alone (HR, 0.52; 95% CI, 0.43-0.64; P < .00001; P
for heterogeneity ¼ .97; I2 ¼ 0%; Figure 2B). In contrast, the
weighted pooled median OS in the bevacizumab arms was 20.4
months (95% CI, 17.3-24.8 months; P for heterogeneity ¼ .85;
I2 ¼ 0%) and ranged from 12.9 to 16.8 months in the 2 control
arms with data available.13,19 The addition of bevacizumab to
chemotherapy reduced the risk of death by approximately 20%
(HR, 0.79; 95% CI, 0.64-0.98; P ¼ .03; P for heterogeneity ¼
1.00, I2 ¼ 0%; Figure 2C).
Compliance and Safety
The treatment regimens are reported in Supplemental Table 3
(available in the online version). The reasons for discontinuation
in the bevacizumab arms were mainly disease progression (48.2%),
toxicity (21.2%), and refusal (11.4%).13,20,22,24 In the control
arms, the corresponding values were 66.2%, 9.8%, and 6.8%.13
Toxicity was reported as the reason for treatment discontinuation
in the bevacizumab arms for 25.4% of the patients in the non-
randomized studies20,22,24 and 17.6% of those in the randomized
trials.13
In the safety analysis (Table 2), which included 75% of all pa-
tients (6 trials),13,19-23 the main all-grade toxicities were hand-footsyndrome (57.4%), diarrhea (42.1%), and hypertension (27%) in
the bevacizumab arms and hand-foot syndrome (38.6%), diarrhea
(34.3%), and nausea (26.4%) in the monochemotherapy-alone
arms. Among the severe toxicities (grade 3-4; Table 3), the more
frequent were hand-foot syndrome (16.3%), diarrhea (15.7%), and
venous thrombosis (7.4%) in the bevacizumab arms and diarrhea
(19.5%), hand-foot syndrome (6.4%), and venous thrombosis
(4.3%) in control arms. The rates of grade 3-4 hypertension were
greater among the bevacizumab-treated patients (6.9% vs. 2%).
The adverse events typically observed with bevacizumab therapy,
such as bleeding and proteinuria (all grades), were also more
frequent with bevacizumab than with chemotherapy alone (24.3%
vs. 6.4% and 25.6% vs. 8.2%, respectively). Grade 3 to 4 hema-
tologic toxicity was rare.
Modiﬁcation of the chemotherapy was reported rarely. In the
largest phase III trial (Avastin With Xeloda in the Elderly
[AVEX]),13 the capecitabine dose modiﬁcation rate was 54% and
43% in the experimental and control arms, respectively. The dose
intensity for the combination arms was generally good when re-
ported, for both chemotherapy (range, 84%-94%) and bevacizumab
(99%) in the 5 arms with data available.13,18,19,21,22 A similar dose
intensity was reported in the 3 ﬂuoropyrimidine arms.13,18,19Clinical Colorectal Cancer Month 2016 - 5
Table 2 All-Grade Toxicities Reported Stratiﬁed by Study Design and Treatment Arm
All-Grade Toxicity
RCTs Not Controlled All
Patients (n)
Point Estimate
(95% CI) Patients (n)
Point Estimate
(95% CI) Patients (n)
Point Estimate
(95% CI)
Bevacizumab arm
Hypertension 58/244 23.8 (18.6-29.6) 35/100 35 (25.6-44.4) 93/344 24 (22.3-31.7)
Venous thrombosis 16/140 11.4 (6.2-16.7) 9/100 9 (3.4-14.6) 25/240 10.4 (6.5-14.3)
Arterial thrombosis 16/244 6.6 (3.5-9.7) 3/75 4 (0-8.4) 19/319 6 (3.4-8.6)
MI ND NA 0/59 0 (0-5.9) 0/59 0 (0-5.9)
GI perforation 3/244 1.2 (0-2.6) 1/16 6.3 (0-18.1) 4/260 1.5 (0-3)
Bleeding 34/140 24.3 (17.2-31.4) ND NA 34/140 24.3 (17.2-31.4)
Proteinuria 48/244 19.7 (14.7-24.7) 25/41 61 (46-75.9) 73/285 25.6 (20.6-30.7)
Neutropenia 7/140 5 (1.4-8.6) 18/145 12.4 (7.1-17.8) 25/285 8.8 (5.8-12.7)
Thrombocytopenia ND NA 32/145 22.1 (15.3-28.8) 32/145 22.1 (15.3-28.8)
Mucositis 20/140 14.3 (8.5-20.1) 38/145 26.2 (19.1-33.4) 58/285 20.4 (15.7-25)
Anemia ND NA 32/145 22.1 (15.3-28.8) 32/145 22.1 (15.3-28.8)
Diarrhea 54/140 38.6 (30.5-46.6) 66/145 45.5 (37.4-53.6) 120/285 42.1 (36.4-47.8)
Hand-foot syndrome 66/140 47.1 (38.9-55.4) 90/145 62.1 (54.2-70) 156/285 57.4 (49-60.5)
Nausea 32/140 22.9 (15.9-29.8) 36/145 24.8 (17.8-31.9) 68/285 23.9 (18.9-28.8)
Neurotoxicity ND NA ND NA ND NA
Control arm
Hypertension 12/245 4.9 (2.2-7.6) NA NA 12/245 4.9 (2.2-7.6)
Venous thrombosis 7/140 5 (1.4-8.6) NA NA 7/140 5 (1.4-8.6)
Arterial thrombosis 8/245 3.3 (1-5.5) NA NA 8/245 3.3 (1-5.5)
MI ND NA NA NA ND NA
GI perforation 0/245 0 (0-1.2) NA NA 0/245 0 (0-1.2)
Bleeding 9/140 6.4 (2.4-10.5) NA NA 9/140 6.4 (2.4-10.5)
Proteinuria 20/245 8.2 (4.7-11.6) NA NA 20/245 8.2 (4.7-11.6)
Neutropenia 1/140 0.7 (0-2.1) NA NA 1/140 0.7 (0-2.1)
Thrombocytopenia ND NA NA NA ND NA
Mucositis 11/140 7.9 (3.4-12.3) NA NA 11/140 7.9 (3.4-12.3)
Anemia ND NA NA NA ND NA
Diarrhea 48/140 34.3 (26.4-42.3) NA NA 48/140 34.3 (26.4-42.3)
Hand-foot syndrome 54/140 38.6 (30.5-46.6) NA NA 54/140 38.6 (30.5-46.6)
Nausea 37/140 26.4 (19.1-33.7) NA NA 37/140 26.4 (19.1-33.7)
Neurotoxicity ND NA NA NA ND NA
Data presented as the number of patients experiencing a speciﬁc adverse event/total number of patients evaluated, along with the point estimate (95% CI).
Abbreviations: CI ¼ conﬁdence interval; GI ¼ gastrointestinal; MI ¼ myocardial infarction; NA ¼ not applicable; ND ¼ not determined; RCT ¼ randomized controlled trial.
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The risk of bias was evaluated on the PFS endpoint, which was less
accurate than theOS endpoint. A selection bias could not be excluded
in 1 of the 3 RCTs because of inadequate reporting.18 For the same
reason, an attrition bias could not be excluded in 2 of the 3
RCTs.18,19 All review authors (V.T., L.P., F.P., G.M.) independently
assessed a high risk of detection bias for each RCT because of the
absence of blinding13,18 or inadequate reporting of applied statistical
methods.19 Details regarding the risk of bias are shown in Figure 3.
Discussion
We performed the present analysis in the attempt to understand
the feasibility, safety, and efﬁcacy of the combination of bev-
acizumab with ﬂuoropyrimidines in elderly or unﬁt patients withnical Colorectal Cancer Month 2016mCRC. The treatment of these patients is a common challenge in
clinical practice, because a worldwide accepted therapeutic standard
is still lacking. It is well known that elderly and unﬁt patients are
generally excluded or underrepresented in RCTs.25 Furthermore,
the elderly patients included in clinical trials are typically a selected
group of subjects with favorable clinical features; therefore, they are
not fully representative of the patients seen in real-world clinical
practices. Moreover, elderly and unﬁt patients are a heterogeneous
group of subjects with as yet undeﬁned rigorous criteria for age
cutoffs and comorbidity assessments. Therefore, elderly patients are
commonly treated with a very conservative approach for the fear of
excessive toxicities or complications related to medical therapies.26
To date, monochemotherapy combined with ﬂuoropyrimidines
(5-FU or capecitabine) is one of the most commonly used
Table 3 Grade 3 to 4 Toxicities Reported Stratiﬁed by Study Design and Treatment Arm
Grade 3-4 Toxicity
RCTs Not Controlled All
Patients (n)
Point Estimate
(95% CI) Patients (n)
Point Estimate
(95% CI) Patients (n)
Point Estimate
(95% CI)
Bevacizumab arm
Hypertension 19/244 7.8 (4.4-11.2) 9/161 5.6 (2.0-9.1) 28/405 6.9 (4.4-9.4)
Venous thrombosis 11/140 7.9 (3.4-12.3) 10/145 6.9 (2.8-11) 21/285 7.4 (4.3-10.4)
Arterial thrombosis 3/140 2.1 (0-4.5) 1/104 1 (0-2.8) 4/244 1.6 (0-3.2)
MI ND NA 1/104 1 (0-2.8) 1/104 1 (0-2.8)
GI perforation 0/140 0 (0-2.1) 2/45 4.4 (0-10.5) 2/185 1.1 (0-2.6)
Bleeding 5/244 2 (0.3-3.8) 1/45 2.2 (0-6.5) 6/289 2.1 (0.4-3.7)
Proteinuria 3/244 1.2 (0-2.6) 3/86 3.5 (0-7.4) 6/330 1.8 (0.4-3.3)
Neutropenia 1/140 0.7 (0-2.1) 3/120 2.5 (0-5.3) 4/260 1.5 (0-3)
Thrombocytopenia ND NA 2/75 2.7 (0-6.3) 2/75 2.7 (0-6.3)
Mucositis 0/140 0.7 (0-2.1) 6/161 3.7 (0.8-6.7) 6/301 2 (0.4-3.6)
Anemia ND NA 1/75 1.3 (0-3.9) 1/75 1.3 (0-3.9)
Diarrhea 48/240 20 (14.9-25.1) 8/166 4.8 (1.6-8.1) 56/356 15.7 (11.9-19.5)
Hand-foot syndrome 21/140 15 (9.1-20.9) 28/161 17.4 (11.5-23.3) 49/301 16.3 (12.1-20.5)
Nausea 1/140 0.7 (0-2.1) 2/120 1.7 (0-4) 3/260 1.2 (0-2.5)
Neurotoxicity ND NA ND NA ND NA
Control arm
Hypertension 5/245 2 (0.3-3.8) NA NA 5/245 2 (0.3-3.8)
Venous thrombosis 6/140 4.3 (0.9-7.6) NA NA 6/140 4.3 (0.9-7.6)
Arterial thrombosis 1/140 0.7 (0-2.1) NA NA 1/140 0.7 (0-2.1)
MI ND 4.3 (0.9-7.6) NA NA ND 4.3 (0.9-7.6)
GI perforation 0/140 0 (0-2.1) NA NA 0/140 0 (0-2.1)
Bleeding 3/245 1.2 (0-2.6) NA NA 3/245 1.2 (0-2.6)
Proteinuria 0/245 0 (0-1.2) NA NA 0/245 0 (0-1.2)
Neutropenia 1/140 0.7 (0-2.1) NA NA 1/140 0.7 (0-2.1)
Thrombocytopenia ND NA NA NA ND NA
Mucositis 1/140 0.7 (0-2.1) NA NA 1/140 0.7 (0-2.1)
Anemia ND NA NA NA ND NA
Diarrhea 47/241 19.5 (14.5-24.5) NA NA 47/241 19.5 (14.5-24.5)
Hand-foot syndrome 9/140 6.4 (2.4-10.5) NA NA 9/140 6.4 (2.4-10.5)
Nausea 0/140 0 (0-2.1) NA NA 0/140 0 (0-2.1)
Neurotoxicity ND NA NA NA ND NA
Data presented as number of patients experiencing a speciﬁc adverse event/total number of patients evaluated and point estimate (95% CI).
Abbreviations: CI ¼ conﬁdence interval; GI ¼ gastrointestinal; MI ¼ myocardial infarction; NA ¼ not applicable; ND ¼ not determined; RCT ¼ randomized controlled trial.
Carmine Pinto et altreatments.27 Retrospective data have shown that in elderly or unﬁt
patients, the use of bevacizumab is usually limited compared with
that use in a younger population. This is mainly because clinicians
are concerned about possible cardiovascular toxicities, although
several trials have indicated the signiﬁcant beneﬁt afforded by the
addition of bevacizumab to ﬂuoropyrimidines compared with ﬂu-
oropyrimidines alone.16,28
Therefore, the aim of the present meta-analysis was to only select
trials reporting data for elderly or unﬁt patients treated with a
backbone chemotherapy of ﬂuoropyrimidines alone combined with
bevacizumab. Our results demonstrated clinically meaningful im-
provements in terms of activity and efﬁcacy provided by the addi-
tion of bevacizumab to ﬂuoropyrimidines. The weighted ORR was
33.3%. Also, by pooling the data from the RCTs, the OR forprogression was 2.05 in favor of bevacizumab (P ¼ .004). The
overall-weighted PFS was 9.4 months. By pooling the data from the
RCTs, the HR for progression was 0.52 in favor of bevacizumab
(P < .001). Finally, the weighted OS was 20.4 months; by pooling
the RCT data, the HR for death was 0.64 in favor of bevacizumab
(P ¼ .03). We believe these ﬁndings are not only statistically sig-
niﬁcant but also relevant from a clinical viewpoint for this popu-
lation of patients with unfavorable medical features.
The safety proﬁle seems acceptable and manageable. The increase
in all-grade toxicities was not surprising, and the incidence of grade
3-4 toxicity was only slightly increased by the addition of bev-
acizumab. In particular, the frequency of clinically harmful toxicities
(eg, arterial thrombosis, myocardial infarction, gastrointestinal
perforation, and bleeding) ranged from 1% to 2%. Furthermore, noClinical Colorectal Cancer Month 2016 - 7
Figure 3 Risk of Bias Assessment, Evaluated on Progression-
Free Survival Endpoint, of the 3 Randomized
Controlled Trials Included in the Meta-Analysis
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8 - Clitrial reported unexpected toxicities. These results compare well with
published data for younger patients.29
Our analysis had several limitations. First, our study was not a
pooled analysis of raw data from individual patients but a meta-
analysis of summary statistics of published data. Therefore, the
heterogeneity of trial design, patient inclusion criteria, and treat-
ment administration should be considered as potential biases.
However, to limit this problem, we decided to carefully select the
trials to be included in our analysis. In particular, we selected only
prospective trials reporting data from elderly or unﬁt patients treated
in ﬁrst-line with monochemotherapy with 5-FU or capecitabine
with or without bevacizumab. Also, we excluded trials of Asian
patients. A second limitation lies in the quality of published data in
this setting. Despite our careful selection, the criteria for patient
accrual were often poorly deﬁned (“patient deemed unsuitable for
combination therapy”). Also, the reported data on comorbidity
assessment and treatment modulation and discontinuation were
sometime incomplete. Once more, in this scenario, it would only be
possible to have more robust data by increasing the number of
patients analyzed (782 in our pooled analysis). Finally, we reported
data derived from the analysis of published trials; therefore, some
degree of patient selection was present (ie, Eastern Cooperative
Oncology Group performance status was > 1 for only 13% of
patients). However, the median age of the subjects included in the
analysis was relatively old (75 years), and the frequency of comor-
bidities was considerable (hypertension in 54%, cardiomyopathy in
30%, diabetes in 20%, vascular accidents in 11%), suggesting that
our studied population was the target population as we had planned.
The present analysis showed that bevacizumab added to ﬁrst-line
ﬂuoropyrimidine chemotherapy for elderly or unﬁt patients with
mCRC provides statistically signiﬁcant and clinically meaningful
advantages in ORR, PFS, and OS. Currently, only few data are
available regarding upfront treatment of elderly or unﬁt patients
with mCRC using anti-endothelial growth factor receptor agents asnical Colorectal Cancer Month 2016monotherapy.30 The available data from retrospective analyses or
small phase II trials31,32 are intriguing; however, their results are
difﬁcult to translate into daily practice. A randomized study of
elderly or unﬁt patients with mCRC and RAS/BRAF wild-type
tumors would be desirable to formally conﬁrm the efﬁcacy of
anti-endothelial growth factor receptor agents as single-agent ﬁrst-
line therapy. We believe the optimal selection of ﬁrst-line treatment
in this population is particularly important, because of the limited
use of subsequent lines of therapy (the rate of second-line therapies
ranged from 37% to 50% in the trials we analyzed). Although the
overall incidence of adverse events was slightly increased by the
addition of bevacizumab, the safety proﬁle of the treatment did not
differ signiﬁcantly from that of younger patients. Therefore, older
age or the presence of some comorbidities should not be considered
as an absolute contraindication for the addition of bevacizumab to
ﬂuoropyrimidine-based chemotherapy. Moreover, it should be
noted that concomitant anticoagulant therapy, if indicated, could be
safely administered with bevacizumab.33 Nevertheless, a careful
assessment of the patient’s medical history with the identiﬁcation of
clinically relevant comorbidities (in particular, cardiovascular
events  6 months before treatment start) and potential risk factors
(eg, uncontrolled hypertension, unstable angina, and arrhythmia
requiring treatment) is necessary to minimize treatment-related
toxicities and increase the therapeutic ratio of treatment.
The strength of our results are potentially limited by the overall
quality of the trials conducted in elderly and unﬁt patients, which
was generally quite low owing to several factors, including the
relatively low patient number, the equivocal criteria used for the
deﬁnition of “elderly,” and the variable assessment of comorbidities.
Further efforts to conduct high-quality prospective trials with
elderly or unﬁt mCRC patients is needed, and it is highly recom-
mended that these trials include a comprehensive geriatric assess-
ment and the evaluation of important endpoints such as changes in
functional, mental, and comorbid status and quality of life. In
particular, a formal comparison between 5-FU or capecitabine plus
bevacizumab and dose-adapted doublet chemotherapy in the geri-
atric population is warranted. Similarly, it would be interesting to
address the comparison between capecitabine plus bevacizumab
versus capecitabine and oxaliplatin plus bevacizumab, although the
latter combination seems feasible.34 These comparisons should be
prospectively tested in randomized trials, which could include
evaluations of the quality of life and pharmacoeconomics aspects.
The results of these studies are eagerly awaited by the oncologic
community.Conclusion
The addition of bevacizumab to ﬁrst-line ﬂuoropyrimidine-based
chemotherapy in elderly or unﬁt patients with mCRC is feasible
without particular safety concerns and provides relevant results in
terms of both activity and efﬁcacy. This combination should
therefore represent an important treatment option for this complex
group of patients.Clinical Practice Points
 A therapeutic standard for elderly and unﬁt patients with mCRC
is still lacking.
Carmine Pinto et al The present meta-analysis tested bevacizumab with ﬂuoropyr-
imidines as ﬁrst-line therapy.
 PFS and OS were signiﬁcantly increased with the combination of
bevacizumab and a ﬂuoropyrimidine.
 The safety proﬁle was acceptable, without particular concerns.
 First-line bevacizumab with ﬂuoropyrimidines is feasible for
these complex patients.Acknowledgments
Medical writing support and editorial assistance was provided by
Clara Ricci, PhD, and Colin G. Egan, PhD (Primula Multimedia
S.r.L., Pisa). A restricted grant was provided by Roche S.p.A. Roche
was not involved in the study design, collection, analysis, or inter-
pretation of data, writing of the report, or the decision to submit the
report for publication.
Disclosure
The authors declare that they have no competing interests.Supplemental Data
Supplemental tables accompanying this article can be found in
the online version at http://dx.doi.org/10.1016/j.clcc.2016.08.006.References
1. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin
2014; 64:104-17.
2. Puts MTE, Hardt J, Monette J, Girre V, Springall E, Alibhai SMH. Use of
geriatric assessment for older adults in the oncology setting: a systematic review.
J Natl Cancer Inst 2012; 104:1133-63.
3. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential
and combination chemotherapy for patients with poor prognosis advanced colo-
rectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370:
143-52.
4. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination
chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal
cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370:135-
42.
5. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and
mitomycin in ﬁrst-line treatment of metastatic colorectal cancer: results of the
Australasian Gastrointestinal Trials Group randomized phase III MAX study.
J Clin Oncol 2010; 28:3191-8.
6. Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination
chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05):
an open-label, randomised, phase 3 trial. Lancet Oncol 2011; 12:1032-44.
7. Biganzoli L, Lichtman S, Michel JP, et al. Oral single-agent chemotherapy in older
patients with solid tumours: a position paper from the International Society of
Geriatric Oncology (SIOG). Eur J Cancer 2015; 51:2491-500.
8. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/ﬂuorouracil combination in
ﬁrst-line therapy of older and younger patients with metastatic colorectal cancer:
combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol
2008; 26:1443-51.
9. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and ef-
ﬁcacy of oxaliplatin plus ﬂuorouracil/leucovorin administered bimonthly in elderly
patients with colorectal cancer. J Clin Oncol 2006; 24:4085-91.
10. Kim JH. Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol
2015; 21:5158-66.
11. Landre T, Uzzan B, Nicolas P, et al. Doublet chemotherapy vs. single-agent
therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-
analysis. Int J Colorectal Dis 2015; 30:1305-10.12. Aprile G, Fontanella C, Lutrino ES, et al. Angiogenic inhibitors for older patients
with advanced colorectal cancer: does the age hold the stage? World J Gastroenterol
2013; 19:2131-40.
13. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus
capecitabine alone in elderly patients with previously untreated metastatic colo-
rectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013;
14:1077-85.
14. Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly
and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-
label, randomised factorial trial. Lancet 2011; 377:1749-59.
15. Doat S, Thiébaut A, Samson S, Ricordeau P, Guillemot D, Mitry E. Elderly pa-
tients with colorectal cancer: treatment modalities and survival in France. National
data from the ThInDiT cohort study. Eur J Cancer 2014; 50:1276-83.
16. Parakh S, Wong H, Rai R, et al. Patterns of care and outcomes for elderly pa-
tients with metastatic colorectal cancer in Australia. J Geriatr Oncol 2015; 6:
387-94.
17. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med 2009; 151:264-9.
18. Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no
more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis
from the AGITG MAX trial: an international randomised controlled trial of
capecitabine, bevacizumab and mitomycin C. Ann Oncol 2012; 23:1531-6.
19. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus
ﬂuorouracil and leucovorin in ﬁrst-line metastatic colorectal cancer: results of a
randomized phase II trial. J Clin Oncol 2005; 23:3697-705.
20. Naeim A, Ward PR, Wang HJ, et al. A phase II trial of frontline capecitabine and
bevacizumab in poor performance status and/or elderly patients with metastatic
colorectal cancer. J Geriatr Oncol 2013; 4:302-9.
21. Vrdoljak E, Omrcen T, Boban M, Hrabar A. Phase II study of bevacizumab in
combination with capecitabine as ﬁrst-line treatment in elderly patients with
metastatic colorectal cancer. Anticancer Drugs 2011; 22:191-7.
22. Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab as ﬁrst-line
treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 2010;
102:1468-73.
23. Puthillath A, Mashtare T, Wilding G, et al. A phase II study of ﬁrst-line biweekly
capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
Crit Rev Oncol Hematol 2009; 71:242-8.
24. Hofheinz R, Petersen V, Kindler M, et al. Bevacizumab in ﬁrst-line treatment of
elderly patients with metastatic colorectal cancer: German community-based
observational cohort study results. BMC Cancer 2014; 14:761.
25. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age
or older in cancer clinical trials. J Clin Oncol 2003; 21:1383-9.
26. Quipourt V, Jooste V, Cottet V, Faivre J, Bouvier AM. Comorbidities alone do
not explain the undertreatment of colorectal cancer in older adults: a French
population-based study. J Am Geriatr Soc 2011; 59:694-8.
27. Seal BS, Sullivan SD, Ramsey SD, et al. Systemic therapy for colorectal cancer:
patterns of chemotherapy and biologic therapy use in nationally representative US
claims database. BioDrugs 2014; 28:229-36.
28. Fu AZ, Tsai HT, Marshall JL, Freedman AN, Potosky AL. Utilization of bev-
acizumab in US elderly patients with colorectal cancer receiving chemotherapy.
J Oncol Pharm Pract 2014; 20:332-40.
29. Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to ﬁrst-line
chemotherapy in advanced colorectal cancer: a systematic review and meta-
analysis, with emphasis on chemotherapy subgroups. BMC Cancer 2012; 12:89.
30. Rosati G, Aprile G, Cardellino GG, Avallone A. A review and assessment of
currently available data of the EGFR antibodies in elderly patients with metastatic
colorectal cancer. J Geriatr Oncol 2016; 7:134-41.
31. Pietrantonio F, Cremolini C, Aprile G, et al. Single-agent panitumumab in frail
elderly patients with advanced RAS and BRAF wild-type colorectal cancer: chal-
lenging drug label to light up new hope. Oncologist 2015; 20:1261-5.
32. Sastre J, Massuti B, Pulido G, et al. First-line single-agent panitumumab in frail
elderly patients with wild-type KRAS metastatic colorectal cancer and poor
prognostic factors: a phase II study of the Spanish Cooperative Group for the
treatment of digestive tumours. Eur J Cancer 2015; 51:1371-80.
33. Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events
in bevacizumab-treated cancer patients who received full-dose anticoagulation and
remained on study. Br J Cancer 2011; 104:413-8.
34. Feliu J, Salud A, Safont MJ, et al. First-line bevacizumab and capecitabinee
oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br
J Cancer 2014; 111:241-8.
35. Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of ﬂuorouracil with
leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III
trial—Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7:1419-26.Clinical Colorectal Cancer Month 2016 - 9
Supplemental Table 1 Characteristics of 8 Studies Included in the Meta-Analysis
Investigator Year Controlled Design International
Geographic Area Recruitment Patients (n)
USA Europe Other Start End Bevacizumab Control
Cunningham et al,13 2013 2013 Yes RCT, phase III, multicenter Yes No Yes Canada, Mexico, South Korea July 2007 December 2010 140 140
Price et al,18 2012 2012 Yes RCT, phase II/III, multicenter Yes No Yes Australia, New Zealand July 2005 June 2007 32 37
Kabbinavar et al,19 2005 2005 Yes RCT, phase II, multicenter Yes Yes No Australia, New Zealand August 2000 July 2002 104 105
Naeim et al,20 2013 2013 No Phase II, multicenter No Yes No None October 2005 February 2009 45 -
Vrdoljak et al,21 2011 2011 No Phase II, single center No No Yes None June 2007 November 2008 41 -
Feliu et al,22 2010 2010 No Phase II, multicenter No No Yes None August 2006 January 2008 59 -
Puthillath et al,23 2009 2009 No Phase II, single center No Yes No None December 2004 April 2007 16 -
Hofheinz et al,24 2014 2014 No Prospective cohort, multicenter No No Yes None January 2005 June 2009 63 -
Abbreviation: RCT ¼ randomized controlled trial.
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Supplemental Table 2 Major Eligibility Criteria for Included Studies
Investigator
Baseline Characteristics Clinical Characteristics Previous Treatment
Patient Age
(Years)
ECOG
PS
Life Expectancy
at Enrollment
(mo)
Judgement of Treating
Investigator mCRC Diagnosis Measurable Disease Metastatic Disease Early Disease
Cunningham
et al,13 2013
70 0-2 3 Not candidate for combination CT
with IRI or OXA or curative
resection of metastatic lesions
Cytologically or histologically
proven CA of colon or rectum,
or both
1 Measurable lesion;
evaluable disease according
to RECIST, version 1.0
No previous CT for mCRC Adjuvant (neoadjuvant) CT
completed >6 mo before
start of study treatment; no
adjuvant anti-VEGF treatment
Price et al,18 2012 75 0-2 3 Considered suitable for
capecitabine monotherapy
Histologically proven
colorectal ACA
Measurable or nonmeasurable
unresectable metastatic disease
No previous CT for mCRC Adjuvant CT completed
>6 mo before disease
relapse
Kabbinavar et al,19
2005
65a 1-2a NR Not candidate for ﬁrst-line
IRI-containing therapy
Histologically proven mCRC Measurable metastatic disease Untreated mCRC;
previous RT to abdomen
or pelvisa
NR
Naeim et al,20 2013 >18 or >70b 2 or 1b NR NR Histologically proven ACA of
colon
1 Measurable lesion according
to RECIST, version 1.0
No previous CT for mCRC Adjuvant CT completed
>6 mo before diagnosis of
metastatic disease
Vrdoljak et al,21
2011
70 0-2 3 NR Cytologically or histologically
proven colorectal ACA
1 Lesion unidimensionally
measurable by computed
tomography (RECIST, version 1.0)
No previous CT for mCRC Adjuvant CT completed
>6 mo before trail
enrollment
Feliu et al,22 2010 70 0-2 3 Unsuitable for receiving
combination OXA or IRI CT
Histologically proven mCRC 1 Lesion unidimensionally
measurable by computed
tomography (RECIST, version 1.0)
No previous CT for mCRC;
earlier RT for mCRC
permitted if completed
6 wk before study
inclusion and if untreated
measurable disease
remained
Disease free 6 mo after
adjuvant/neoadjuvant CT
completion
Puthillath et al,23
2009
70 0-2 3 NR Histologically proven mCRC Measurable disease, deﬁned
as 1 lesion >20 mm on
conventional computed
tomography or >10 mm on
spiral computed tomography
scan
No previous CT for mCRC Only previous 5-FU/LV
adjuvant CT allowed,
provided it was completed
>6 mo before metastatic
disease development
Hofheinz et al,24
2014
75 NR NR NR mCRC diagnosis NR No previous CT for mCRC NR
Abbreviations: 5-FU ¼ 5-ﬂuorouracil; ACA ¼ adenocarcinoma; CA ¼ carcinoma; CT ¼ chemotherapy; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; IRI ¼ irinotecan; LV ¼ leucovorin; mCRC ¼ metastatic colorectal cancer; NR ¼ not reported;
OXA ¼ oxaliplatin; RECIST ¼ Response Evaluation Criteria in Solid Tumors; RT ¼ radiotherapy; VEGF ¼ vascular endothelial growth factor.
aAt least 1 of these characteristics was required.
bBoth conditions requested (ie, age > 18 years and ECOG PS 2 or age > 70 years and ECOG PS 1).
C
arm
ine
P
into
et
al
ClinicalColorectalCancer
Month
2016 -9.e2
Supplemental Table 3 Treatment Regimen, Compliance, and Second-Line Therapy in 8 Included Studies
Investigator
Treatment
Arm Regimen
Median Duration;
Median Dose Intensity
Patients Receiving
Modiﬁed Dosea
Patients Administered
Second-Line Therapy
Overall
Bevacizumab
Only
Cunningham et al,13 2013 Experimental Capecitabine (1000 mg/m2 p.o. twice daily on days 1-14); bevacizumab
(7.5 mg/kg I.V. on day 1), every 3 wk
5.8 mo; 9 cycles; capecitabine,
85.2%b; bevacizumab, 99.1%b
72/134 (54) 52/140 (37.1) 8/140 (5.7)
Control Capecitabine (1000 mg/m2 p.o. twice daily on days 1-14), given every 3 wk 4.2 mo; 6 cycles; capecitabine,
89.6%b
59/136 (43) 52/140 (37.1) 11/140 (7.9)
Price et al,18 2012 Experimental Capecitabine (1.25 g/m2 twice daily on days 1-14 every 3 wk); investigators could
nominate a lower starting dosage (ie, 1 g/m2 twice daily) for patients considered
at risk of toxicity; bevacizumab (7.5 mg/kg on day 1) every 3 wk
8 cycles; capecitabine, 85.6%;
bevacizumab, 99.3%
NR NR NR
Control Capecitabine (1.25 g/m2 twice daily on days 1-14 every 3 wk); investigators could
nominate a lower starting dosage (ie, 1 g/m2 twice daily) for patients considered
at risk of toxicity
7 cycles; capecitabine, 93.2% NR NR NR
Kabbinavar et al,19 2005 Experimental 5-FU/LV regimen: LV 500 mg/m2 over 2 h and 5-FU 500 mg/m2 as a bolus
midway through LV infusion (Roswell Park regimenc), administered weekly for ﬁrst
6 wk of each 8-wk cycle; total administration, 96 wk; bevacizumab, 5 mg/kg
every 2 wk
31 wk; 5-FU: 84%; bevacizumab, NR NR 52/104 (50) NR
Control 5-FU/LV regimen: LV 500 mg/m2 over 2 h and 5-FU 500 mg/m2 as bolus midway
through LV infusion (Roswell Park regimenc), administered weekly for ﬁrst 6 wk of
each 8-wk cycle; total administration, 96 wk; placebo
23 wk; 5-FU, 92%; bevacizumab, NR NR 52/105 (50) NR
Naeim et al,20 2013 Experimental Capecitabine (1000 mg/m2 p.o. twice daily for 2 wk, followed by 1 wk of rest);
bevacizumab (7.5 mg/kg I.V., every 3 wk)
6 cycles; NR 13/45 (28.9) NR NR
Vrdoljak et al,21 2011 Experimental Capecitabine (1000 mg/m2 twice daily for 2 wk, followed by 1 week of rest);
bevacizumab (7.5 mg/kg on the ﬁrst day of each 3-wk cycle)
12 cycles; capecitabine, 94%;
bevacizumab, NR
24/41 (58.5) 11/41 (26.8) NR
Feliu et al,22 2010 Experimental Capecitabine (1250 mg/m2 twice daily if CrCl >50 mL/min; 950 mg/m2 twice
daily if CrCl 30-50 mL/min); capecitabine administered for 2 wk, followed by
1 wk of rest; bevacizumab (7.5 mg/kg on ﬁrst day of each 3-wk cycle)
7.1 cyclesb; capecitabine, 94.2%b;
bevacizumab, 99.0%b
NR NR NR
Puthillath et al,23 2009 Experimental Capecitabine (1500 mg/m2 p.o. twice daily for 7 days every 2 wk); bevacizumab
(5 mg/kg I.V., every 2 wk)
12 cycles; NR NR 13/16 (81.3) NR
Hofheinz et al,24 2014 Experimental Capecitabine or 5-FU at physician discretion; bevacizumab 5-10 mg/kg every
2 wk or 7.5-15 mg/kg every 3 wk at physician discretion
NR NR NR NR
Abbreviations: 5-FU ¼ 5-ﬂuorouracil; CrCl ¼ creatinine clearance; I.V. ¼ intravenous; LV ¼ leucovorin; NR ¼ not reported; p.o. ¼ orally.
aRegimen (eg, capecitabine plus bevacizumab, only capecitabine).
bMean value.
cPetrelli et al.35
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